Compare Agilent Technologies Inc (A) vs Cronos Group Inc (CRON) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Cronos Group Inc — how do they compare? Agilent Technologies Inc trades at $128.24 (market cap $37.04B), while Cronos Group Inc trades at $2.74 (market cap $1.03B). The key difference: Agilent Technologies Inc is far larger — about 36× Cronos Group Inc's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| A | CRON | |
|---|---|---|
Market Cap | $37.04B | $1.03B |
Sector | Health | Health |
52-Week High | $157.20 | $3.27 |
52-Week Low | $110.24 | $1.95 |
Enterprise Value | $38.59B | $205.93M |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Cronos Group (CRON) trades at $2.75, down 3.85% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 revenue growth of 40% year-over-year to $45.2 million, achieving record net revenue and gross profit. However, net income remains negative at -$9.45 million for 2025, though margins have improved significantly from prior years. Recent news highlights expansion in Canada and Israel, along with a share repurchase program extension.
Outlook is cautiously optimistic with strong revenue growth and market share gains, but profitability challenges and intense cannabis competition pose risks. Analyst sentiment is mixed with 60% hold ratings. Key catalysts include international expansion and execution on cost controls, while regulatory uncertainty and cash flow volatility remain headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
